FinanceEvolent Health: A High-Risk, High-Reward Investment Opportunity
Evolent Health, Inc. (EVH) is currently a 'Buy' recommendation despite its significant debt and ongoing net losses. The company's stock is trading at a heavily discounted valuation, primarily due to nearly $967 million in long-term debt and persistent GAAP losses. Management has outlined a strategy to achieve over 25% revenue growth and adjusted EBITDA of at least $150 million by 2027, aiming to improve its financial structure. The investment thesis is supported by an industry recovery and strong growth in specialty care revenue, positioning EVH as a turnaround opportunity with both considerable risk and potential reward.